Levels of reduced and oxidized coenzymeQ-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process

Neuroscience Letters

Volumn 469, Issue 1, 2010, Pages 159-163

  Isobe, Chiaki ^a   Abe, Takashi ^a   Terayama, Yasuo ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

8 Hydroxy 2 deoxyguanosine; Cerebrospinal fluid; Free radicals; Oxidized coenzymeQ 10; Parkinson's disease; Reduced coenzymeQ 10

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; DNA; UBIDECARENONE;

AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE DURATION; DNA DAMAGE; ELECTROCHEMICAL DETECTION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; MITOCHONDRION; NERVE DEGENERATION; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL;

AGED; DEOXYGUANOSINE; DNA DAMAGE; FEMALE; HUMANS; MALE; MITOCHONDRIA; OXIDATION-REDUCTION; OXIDATIVE STRESS; PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX; UBIQUINONE;

EID: 72649092390     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.11.065     Document Type: Article

References (34)

1. Abe T., Isobe C., Murata T., Sato C., and Tohgi H. Alteration of 8-hydroxy-guanosine concentration in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci. Lett. 336 (2003) 105-108
2. Akao Y., Maruyama W., Shimizu S., Nakagawa Y., Shamoto-Nagai M., Youdim M.B., Tsujimoto Y., and Naoi M. Mitochondrial permeability transition mediates apoptosis induced by N-methyl (R) salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem. 82 (2002) 913-923
3. Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., Jenner P., and Halliwell B. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanosine levels in substantia nigra. J. Neurochem. 69 (1997) 1196-1203
4. Altamura S., and Muckenthaler M.U. Iron toxicity in diseases of aging, Alzheimer's disease, Parkinson's disease. J. Alzheimers Dis. 16 (2009) 879-895
5. Betarbet R., Sherer T.B., MacKenzie G., Garcia-Osuna M., Panov A.V., and Greenamyre J.T. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat. Neurosci. 3 (2000) 1301-1306
6. Collins M.A., and Neafsey E.J. Potential neurotoxic "agents provacateurs" in Parkinson's disease. Neurotoxicol. Teratol. 24 (2002) 571-577
7. Ebadi M., Govitrapong P., Sharma S., Muralikrishnan D., Shavali S., Pellett L., Schafer R., Albano C., Eken J., and Ubiquinone. (Coenzyme Q10) and mitochondrial in oxidative stress of Parkinson's disease. Biol. Signal. Recept. 10 (2002) 224-263
8. Forno L.S., and Langston J.W. Lewy bodies and aging: relation to Alzheimer's and Parkinson's diseases. Neurodegener. Dis. 2 (1993) 19-24
9. Gotz M.E., Freyberger A., and Riederer P. Oxidative stress: a role in the pathogenesis of Parkinson's disease. J. Neural. Transm. 29 (1990) 241-249
10. Hattori N., Tanaka M., Osawa T., and Mizuno Y. Immunohistochemical studies on complex I, II, III, and IV of mitochondria in Parkinson's disease. Ann. Neurol. 30 (1991) 563-571
11. Hirai K., Aliev G., Nunomura A., Fujioka H., Russel R.L., Atqoos C.S., Johnson A.B., Kress Y., Vinters H.V., Tabaton M., Shimohama S., Cash A.D., Siedlak S.L., Harris P.L., Jones P.K., Petersen R.B., Perry G., and Smith M.A. Mitochondrial abnormalities in Alzheimer's disease. J. Neurosci. 21 (2001) 3017-3023
12. Hughes A.J., Daniel S.E., Kifford L., and Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatr. 55 (1992) 181-184
13. Isobe C., Murata T., Sato C., and Terayama Y. Increased of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson's disease. J. Clin. Neurosci. 14 (2007) 340-343
14. Jiménez-Jiménez F.J., Molina J.A., de Bustos F., García-Redondo A., Gómez- Escalonilla C., Martínez-Salio A., Berbel A., Camacho A., Zurdo M., Barcenilla B., Enríquez de Salamanca R., and Arenas J. Serum levels of coenzyme Q10 in patients with Parkinson's disease. J. Neural. Transm. 107 (2000) 177-181
15. Matsubara T., Azuma T., Yoshida S., and Yamagami T. Serum coenzyme Q10 level in Parkinson syndrome. In: Folkers K., Littarru G.P., and Yamagami T. (Eds). Biomedical and Clinical Aspects of Coenzyme Q (1991), Elsevier Science Publishers, New York 159-166
16. Mizuno Y., Matsuda S., Yoshino H., Mori H., Hattori N., and Ikebe S. An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 35 (1994) 204-210
17. Nunomura A., Perry G., Zhang J., Montine T.J., Takeda A., Chiba S., and Smith M.A. RNA oxidation in Alzheimer and Parkinson diseases. J. Anti-Aging Med. 2 (2002) 227-230
18. Okamoto T., Fukui K., Nakamoto M., Kishi T., Okishio T., Yamagami T., Kanamori N., Kishi H., and Hiraoka E. High-performance liquid chromatography of coenzyme Q-related compounds and its application to biological materials. J. Chromatogr. 342 (1985) 35-46
19. Olanow C.W., Hauser R.A., Jankovic J., Langston W., Lang A., Poewe W., Tolosa E., Stocchi F., Melamed E., Eyal E., and Rascol O. A randomized, double-blind, placebo-controlled delayed start study to assess rasagilline as disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov. Disord. 23 (2008) 2194-2201
20. Payami H., and Zareparsi S. Genetic epidemiology of Parkinson's disease. J. Geriatr. Psychiatr. Neurol. 11 (1998) 98-106
21. Richte C., Park J.W., and Ames B.N. Normal oxidative damage to mitochondrial and nuclear DNA is extensive. Proc. Natl. Acad. Sci. U.S.A. 85 (1988) 6465-6467
22. Sato S., Mizuno Y., and Hattori N. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson's disease. Neurology 64 (2005) 1081-1083
23. Schapira A.H.V., Cooper J.M., Dexter D., Clark J.B., Jenner P., and Marsden C.D. Mitochondrial complex I deficiency in Parkinson's disease. J. Neurochem. 54 (1990) 823-827
24. Shelley M.L. (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic. Biol. Med. 25 (1998) 169-174
25. Shigenaga M.K., Gimeno C.J., and Ames B.N. Urinary 8-hydroxy-2′-deoxyguanosine as a biomarker of in vivo oxidative DNA damage. Proc. Natl. Acad. Sci. U.S.A. 86 (1989) 9697-9701
26. Shults C.W., Haas R.H., Passov D., and Beal M.F. Coenzyme Q10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects. Ann. Neurol. 42 (1997) 261-264
27. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., Kompoliti K., Perlmutter J.S., Reich S., Stern M., Watts R.L., Kurlan R., Molho E., Harrison M., Lew M., and Parkinson Study Group. Effects of Coenzyme Q10 in early Parkinson's disease. Evidence of slowing the functional decline. Arch. Neurol. 59 (2002) 1541-1550
28. Spencer J.P.E., Jenner P., and Halliwell B. Superoxide-dependent depletion of reduced glutathione by l-DOPA and dopamine. Relevance to Parkinson's disease. Neuro-Report 5 (1995) 1480-1484
29. Warmer W.G., and Wei R.R. In vitro photooxidation of nucleic acids by ultraviolet A radiation. Photochem. Photobiol. 6 (1997) 560-563
30. Wooten G.F. Neurochemistry and neuropharmacology of Parkinson's disease. In: Watts R.L., and Koller W. (Eds). Movement Disease Neurologic Principles and Practice (1997), McGraw-Hill Press, New York 153-160
31. Yamamoto Y., and Yamashita S. Plasma ratio of ubiquinol and ubiquinone as a marker of oxidative stress. Mol. Aspects Med. 18 (1997) S79-84
32. Yamamoto Y., Kawamura M., and Tatsuno. Formation of lipid hydroperoxides in the cupric ion-induced oxidation of plasma and low density lipoprotein. In: Davies K.J.A. (Ed). Oxidative Damage & Repair (1991), Pergamon Press, New York 287-291
33. Zhang J., Perry G., Smith M.A., Robertson D., Olson S.l., Graham D.J., and Montine T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 154 (1999) 1423-1429
34. Zhang J., Perry G., Smith M.A., Robertson D., Olson S.J., Graham D.G., and Montine T.J. Parkinson's disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am. J. Pathol. 154 (1999) 1423-1429